Stockscreener 앱 받기
7.38
1.37%
0.10
시장 영업 전:
7.53
0.15
+2.03%
Rxsight Inc 주식(RXST)의 최신 뉴스
(RXST) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
What analysts say about RxSight Inc. stockRapid profit acceleration - Jammu Links News
RxSight's (RXST) Deteriorating Fundamentals and Regulatory Risks: A Cautionary Tale for Investors - AInvest
RXST BREAKING NEWS: BFA Law is Investigating RxSight, Inc. for Securities Fraud; Contact the Firm about how to Potentially Recover Investment Losses - The Globe and Mail
RxSight Downgraded After Q2 Revenue Miss, FY23 Guidance Cut. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc.RXST - PR Newswire
RxSight's Plunge: Securities Fraud Allegations and the Uncertain Future for RXST Shareholders - AInvest
Investigation Continues: RxSight Investors Urged to Contact Glancy Prongay & Murray LLP - AInvest
Securities Fraud Investigation Into RxSight, Inc. (RXST) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm - The Globe and Mail
RxSight, Inc. (RXST) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - The Globe and Mail
RXSIGHT ALERT: Bragar Eagel & Squire, P.C.Announces - GlobeNewswire
Robbins LLP is Investigating the Officers and Directors of - GlobeNewswire
Robbins LLP is Investigating the Officers and Directors of RxSight, Inc. (RXST) to Determine if They Breached Fiduciary Duties Owed to Shareholders - TradingView
Robbins LLP is Investigating the Officers and Directors of RxSight, Inc. (RXST) to Determine if They Breached Fiduciary Duties Owed to Shareholders - GlobeNewswire Inc.
Steris, Solventum stocks upgraded at Morgan Stanley (STE:NYSE) - Seeking Alpha
RxSight stock rating downgraded by Morgan Stanley on growth concerns - Investing.com Canada
Morgan Stanley Downgrades RxSight Inc. (RXST) to Equalweight - StreetInsider
What makes RxSight Inc. stock price move sharplyFree Stock Market Expert Consultation - beatles.ru
Top 3 Health Care Stocks That Could Blast Off In July - Benzinga
RxSight, Inc. (RXST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - MSN
The Biotech Bubble: RxSight's Downfall and the Dangers of Overvalued Innovation - AInvest
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Stockholders to Connect - ACCESS Newswire
INVESTOR ALERT: Investigation of RxSight, Inc. (RXST) Announced by Holzer & Holzer, LLC - GlobeNewswire
Securities Fraud Investigation Into RxSight, Inc. (RXST) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm - The Globe and Mail
Midday Stock Roundup: Karman Holdings Up Nearly 3% - Orange County Business Journal
Johnson Fistel Begins Investigation on Behalf of RxSight, Inc. (RXST) Shareholders - GlobeNewswire
RxSight and iRobot: Navigating Legal Risks and Financial Declines in Healthcare and Tech - AInvest
Robbins LLP Informs RxSight, Inc. Stockholders that it is Investigating the Officers and Directors of RXST to Determine if They Breached Fiduciary Duties Owed to Shareholders - ACCESS Newswire
RxSight stock falls after Wells, BTIG downgrade on poor results - MSN
RxSight’s 5% Spike: A Technical Rally or Isolated Momentum Play? - AInvest
Securities Fraud Investigation Into RxSight, Inc. (RXST) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The Globe and Mail
RxSight, Inc. Securities Lawsuit Investigation - Claim Depot
RxSight’s 5% Spike: Technical Oversold Triggers and Mixed Peer Signals - AInvest
RxSight's Mysterious 6.7% Spike: Technical Clues Uncovered - AInvest
RxSight Plummets 38%—What’s Driving This Historic Drop? ⚠️ - AInvest
Is RXST's Q4 2024 EPS decline a concern? - AInvest
What's the outlook for RXST's EPS in 2025? - AInvest
Jefferies Downgrades RxSight to Hold From Buy, Adjusts Price Target to $9 From $24 - MarketScreener
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Gain Therapeutics (GANX) and Edwards Lifesciences (EW) - The Globe and Mail
Jefferies downgrades RxSight stock rating to Hold on elongated selling cycles By Investing.com - Investing.com South Africa
Jefferies downgrades RxSight stock rating to Hold on elongated selling cycles - Investing.com Nigeria
Jefferies Downgrades RxSight Inc. (RXST) to Hold - StreetInsider
RxSight(RXST) Plunges 37.84% on Lowered Revenue Outlook - AInvest
RxSight's Revised Guidance Reflects Deeper Market Shifts (Rating Downgrade) (NASDAQ:RXST) - Seeking Alpha
RxSight stock slides on lower Q2 revenue guidance - MSN
Crude Oil Moves Higher; RxSight Shares Plunge - Benzinga
RxSight Stock Drops 50% Following Disappointing Q2 ResultsNews and Statistics - IndexBox
Needham maintains Buy rating on RxSight stock despite near-term concerns - Investing.com Australia
Needham maintains Buy rating on RxSight stock despite near-term concerns By Investing.com - Investing.com South Africa
Why Did RxSight Plunge 49.27%? Revenue Forecast Cut - AInvest
RxSight Stock Sinks 50% as Medical Device Maker Slashes Revenue Outlook - Investopedia
RxSight stock rating downgraded to Neutral by BTIG amid sales challenges - Investing.com Australia
Aehr Test Systems Posts Downbeat Sales, Joins RxSight, Vertical Aerospace And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - 富途牛牛
RxSight’s preliminary Q2 2025 revenue expected to decrease 4% - Medical Buyer
RxSight stock rating downgraded by Wells Fargo amid sales concerns - Investing.com Nigeria
Needham Reiterates Buy Rating on RxSight Inc. (RXST) - StreetInsider
RxSight Plunges 37.29% on Revenue Miss - AInvest
Wells Fargo Downgrades RxSight Inc. (RXST) to Equal Weight - StreetInsider
Transcript : RxSight, Inc., Q2 2025 Earnings Call, Jul 08, 2025 - MarketScreener
1.67%
0.94%
자본화:
|
볼륨(24시간):